Sanofi (SNYNF) Return on Assets (2018 - 2026)
Sanofi's (SNYNF) quarterly Return on Assets came in at 0.0% in Q1 2026, little changed year-on-year from 0.0% in Q1 2025, and down 4.1% quarter-over-quarter from 0.0% in Q4 2025.
Sanofi (SNYNF) Return on Assets (2018 - 2026) Analysis & Trends
Sanofi has disclosed Return on Assets across 3 years of filings, most recently posting 0.0% for Q1 2026.
- Return on Assets for Q1 2026 came in at 0.0%, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY), and the FY2025 annual result was 0.0%, changed 0.0% from the prior year.
- Return on Assets came in at 0.0% for Q1 2026 at Sanofi, down from 0.0% in the prior quarter.
- In the past five years, Return on Assets ranged from a high of 0.0% in Q3 2025 to a low of 0.0% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | 0.00% |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | 0.00% |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 0.00% |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | 0.00% |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | 0.00% |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | 0.00% |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 0.00% |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | 0.00% |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | 0.00% |
| 10 | Sanofi | - | - | 9.49 Bn | 0.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.00% |
| Dec 31, 2025 | 0.00% |
| Sep 30, 2025 | 0.00% |
| Jun 30, 2025 | 0.00% |
| Mar 31, 2025 | 0.00% |
| Dec 31, 2018 | 0.00% |
| Sep 30, 2018 | 0.00% |
| Jun 30, 2018 | 0.00% |
| Mar 31, 2018 | 0.00% |